Mansoor Raza Mirza, M.D

Mansoor Raza Mirza, M.D., is Chief Medical Officer at Acrivon Therapeutics, Inc. 

Dr. Mirza is a world-renowned oncology key opinion leader and clinical investigator. Prior to joining Acrivon, Mansoor most recently served as Chief Oncologist at Copenhagen University National Medical Center (Rigshospitalet) in Denmark. Mansoor is a clinical oncologist, with a primary focus on the treatment of gynecologic cancers. During his distinguished career in academia and clinical practice, he focused on clinical research, international trial collaboration and education, priorities which provided broad experience in clinical trial development, trial conduct and clinical trial regulations. He has led numerous phase I, II and III studies, several leading to U.S. Food and Drug Administration and European Medicines Agency approvals, notably including lead investigator of the first global phase III trial of PARP inhibitors in ovarian cancer (the NOVA study) and the trial of chemotherapy with dostarlimab in first-line treatment of endometrial cancer (the RUBY study). Both trials resulted in an unprecedented improvement in the management of gynecological cancer patients. He has authored over 200 peer reviewed publications including seven in the New England Journal of Medicine (four as first author). In addition to having co-authored European Guidelines in endometrial and vulvar cancers, Mansoor has served as past-chair of European Network of Gynecological Oncological Trial Group (ENGOT) and vice president of European Society of Gynecological Oncology (ESGO), and will be the president of ESGO Congress 2026. Mansoor currently serves on the board of directors of Sera Prognostics, Inc., and Karyopharm Therapeutics Inc. 

He holds a M.D., post-graduate diplomas in surgery and in clinical oncology from the Pirogov Moscow State Medical Institute, Moscow, Russia. He later completed postgraduate education in clinical oncology at the University of Southern Denmark and holds licenses to practice medical and radiation oncology in Denmark.

Jean-Marie Cuillerot

Jean-Marie Cuillerot, M.D., is Chief Medical Officer at Acrivon Therapeutics, Inc. Jean-Marie was previously the Chief Medical Officer at Dragonfly Therapeutics where he established and led a clinical team advancing multiple potential first-in-class assets. Prior to Dragonfly, Jean-Marie was the chief medical officer of Agenus, where he led development activities for five investigational therapies. At EMD Serono, an affiliate of Merck Serono, Jean-Marie served as the global head of clinical development in immuno-oncology (IO) and as the vice president of clinical immunotherapy/IO. He oversaw the company’s IO portfolio which included two checkpoint inhibitors and two immuno-cytokines. Notably, Jean-Marie led the clinical development of avelumab, the first drug approved to treat Merkel cell carcinoma and second-line bladder cancer, from pre-IND though global submissions in record time, an achievement that earned him the Merck CEO Award. From 2007 to 2012, he was at Bristol- Myers Squibb, where he was medical lead for the life cycle management of ipilimumab, an anti-CTLA-4 antibody and the world’s first immune checkpoint therapy for cancer, where he designed and led Phase 2 and Phase 3 studies across multiple indications and supported regulatory filings in the United States and Europe. Earlier in his career, Jean-Marie also served in clinical development at Novartis, as a clinical research physician at the Centre d’Immunologie Pierre Fabre, and as an assistant professor at the Hôpitaux Universitaires de Strasbourg. Jean-Marie received a B.S. in biochemistry, an M.Sc. in cellular and molecular biology and an M.D. at the University Louis Pasteur (Strasbourg, France).